The coming of age for antigen-specific therapy of multiple sclerosis

European Journal of Neurology

Volumn 13, Issue 8, 2006, Pages 793-794

  Steinman, L ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; GLATIRAMER; HLA DR2 ANTIGEN; MYELIN BASIC PROTEIN; TUMOR NECROSIS FACTOR;

ANTIGEN SPECIFICITY; AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TH2 CELL; TREATMENT RESPONSE;

ANTIGENS; HUMANS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS;

EID: 33746424333     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2006.01532.x     Document Type: Editorial

References (14)

1. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2005; 435: 612-619.
2. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nature Reviews Drug Discovery 2005; 4: 510-519.
3. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis and Rheumatism 2001; 44: 1977-1983.
4. Warren KG, Catz I, Ferenczib LZ, Krantz MJ. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis. European Journal of Neurology 2006; 13: 887-895.
5. Sakai K, Zamvil SS, Mitchell DJ, Lim M, Rothbard JB, Steinman L. Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein. Journal of Neuroimmunology 1988; 19: 21-32.
6. Warren KG, Catz I, Steinman L. Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B cell epitope and a model of its unique features. Proceedings of the National Academy of Sciences of the United States of America 1995; 92: 11061-11065.
7. Wucherpfenig KW, Catz I, Hausmann S, Strominger JL, Steinman L, Warren KG. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2 restricted T cell clones from multiple sclerosis patients: identity of key contact residues in the B-cell and T-cell epitopes. Journal of Clinical Investigation 1997; 100: 1114-1122.
8. Kappos L, Comi G, Panitch H et al.and the APL in Relapsing MS Study Group. Induction of a non-encephalitogenic Th2 autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo controlled, randomized phase II trial. Nature Medicine 2000; 6: 1176-1182.
9. Bielekova B, Goodwin B, Richert N et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nature Medicine 2000; 6: 1167-1175.
10. Conlon P, Steinman L. Altered peptide ligand and MS treatment. Science 2002; 296: 1801-1802.
11. Robinson WH, Fontoura P, Lee BJ et al. Reverse genomics: protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nature Biotechnology 2003; 21: 1033-1039.
12. Kanter J, Narayana S, Ho P et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nature Medicine 2006; 12: 138-143.
13. Bar-Or A, Jalili F, Niino M et al. Antigen-specific immunomodulation in multiple sclerosis patients treated with MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin. Multiple Sclerosis 2005; 11: S167.
14. Vollmer T, Lapierre Y, Weiner L et al. Clinical trial of a MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin for treatment of multiple sclerosis. Multiple Sclerosis 2005; 11: S13.